These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32025848)

  • 21. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.
    Mehra N; Sharp A; Lorente D; Dolling D; Sumanasuriya S; Johnson B; Dearnaley D; Parker C; de Bono J
    Clin Genitourin Cancer; 2017 Dec; 15(6):678-684.e1. PubMed ID: 28606735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer.
    Zhuang E; Uchio E; Lilly M; Zi X; Fruehauf JP
    Biomed Pharmacother; 2021 Nov; 143():112226. PubMed ID: 34649352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.
    Obara W; Sato F; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Mimata H; Sugai T; Nakamura Y; Fujioka T
    Cancer Sci; 2017 Jul; 108(7):1452-1457. PubMed ID: 28498618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients.
    Fujita K; Nakai Y; Kawashima A; Ujike T; Nagahara A; Nakajima T; Inoue T; Lee CM; Uemura M; Miyagawa Y; Kaneda Y; Nonomura N
    Cancer Gene Ther; 2017 Jul; 24(7):277-281. PubMed ID: 28497777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
    Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
    Antonarakis ES; Tagawa ST; Galletti G; Worroll D; Ballman K; Vanhuyse M; Sonpavde G; North S; Albany C; Tsao CK; Stewart J; Zaher A; Szatrowski T; Zhou W; Gjyrezi A; Tasaki S; Portella L; Bai Y; Lannin TB; Suri S; Gruber CN; Pratt ED; Kirby BJ; Eisenberger MA; Nanus DM; Saad F; Giannakakou P;
    J Clin Oncol; 2017 Oct; 35(28):3181-3188. PubMed ID: 28632486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
    Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
    Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
    Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.
    Paller CJ; Zahurak ML; Mandl A; Metri NA; Lalji A; Heath E; Kelly WK; Hoimes C; Barata P; Taksey J; Garrison DA; Patra K; Milne GL; Anders NM; Nauroth JM; Durham JN; Marshall CH; Markowski MC; Eisenberger MA; Antonarakis ES; Carducci MA; Denmeade SR; Levine M
    Cancer Res Commun; 2024 Aug; 4(8):2174-2182. PubMed ID: 39076107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
    Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
    Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer.
    Laber DA; Chen MB; Jaglal M; Patel A; Visweshwar N
    Clin Genitourin Cancer; 2018 Dec; 16(6):473-481. PubMed ID: 30072309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.
    Venkitaraman R; Lorente D; Murthy V; Thomas K; Parker L; Ahiabor R; Dearnaley D; Huddart R; De Bono J; Parker C
    Eur Urol; 2015 Apr; 67(4):673-9. PubMed ID: 25457497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
    Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
    Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
    Oudard S; Latorzeff I; Caty A; Miglianico L; Sevin E; Hardy-Bessard AC; Delva R; Rolland F; Mouret L; Priou F; Beuzeboc P; Gravis G; Linassier C; Gomez P; Voog E; Muracciole X; Abraham C; Banu E; Ferrero JM; Ravaud A; Krakowski I; Lagrange JL; Deplanque G; Zylberait D; Bozec L; Houede N; Culine S; Elaidi R
    JAMA Oncol; 2019 May; 5(5):623-632. PubMed ID: 30703190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
    Merseburger AS; Attard G; Åström L; Matveev VB; Bracarda S; Esen A; Feyerabend S; Senkus E; López-Brea Piqueras M; Boysen G; Gourgioti G; Martins K; Chowdhury S
    Lancet Oncol; 2022 Nov; 23(11):1398-1408. PubMed ID: 36265504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
    Harshman LC; Chen YH; Liu G; Carducci MA; Jarrard D; Dreicer R; Hahn N; Garcia JA; Hussain M; Shevrin D; Eisenberger M; Kohli M; Plimack ER; Cooney M; Vogelzang NJ; Picus J; Dipaola R; Sweeney CJ;
    J Clin Oncol; 2018 Feb; 36(4):376-382. PubMed ID: 29261442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer.
    Hatano K; Nishimura K; Nakai Y; Yoshida T; Sato M; Kawashima A; Mukai M; Nagahara A; Uemura M; Oka D; Nakayama M; Takayama H; Shimizu K; Meguro N; Tanigawa T; Yamaguchi S; Tsujimura A; Nonomura N
    Int J Clin Oncol; 2013 Aug; 18(4):704-10. PubMed ID: 22688162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.